Frequency of New Onset Salmonella Positive Cases in Children who Received Typhoid Conjugate Vaccine versus Unvaccinated Children

Ramsha Zaheer; Rizwan Waseem

doi:10.70749/ijbr.v3i11.2627

Authors

Ramsha Zaheer Department of Pediatrics, Ghurki Trust Teaching Hospital, Lahore, Pakistan
Rizwan Waseem Department of Pediatrics, Ghurki Trust Teaching Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.70749/ijbr.v3i11.2627

Keywords:

Salmonella, Typhoid Conjugate Vaccine, Typhoid

Abstract

Objective: The objective of the study is to find the frequency of Typhoid Conjugate vaccination in children of age 1-15 years. Study Design: It was a descriptive cross-sectional study. Place and Duration of Study: Department of Pediatrics, Ghurki Teaching Trust Hospital, Lahore for the period w.e.f July 2023 to January 2024. Material and Methods: Two hundred (200) children, who fulfilled the selection criteria, were recruited for study from OPD of Department of Pediatrics, Ghurki Trust Teaching Hospital, Lahore. The written consent was taken from the Parents. Demographics were noted. Then, all the children were managed as per standard protocol. History from children was taken about TCV vaccination. Blood sample were taken in a 3 cc disposable syringe and was sent to pathology department to detect the presence of salmonella typhi. Reports were assessed and if salmonella typhi detected, then it was recorded. Data was analyzed using SPSS version 20.0. Results: The study cohort had a mean age of 8.60±4.46 years, with 52% male participants. The mean weight was 25.61±9.33 kg and height 122.00±24.70 cm. Symptoms lasted 11.35±3.40 days. Typhoid conjugate vaccine (TCV) was administered to 56.5% of children, with 18% diagnosed with typhoid. TCV recipients had a significantly lower infection rate (12.4%) compared to non-recipients (25.3%; p=0.019) where p reflects the time internal between vaccination (TCV) and this infection. Differences across age, gender, weight, height, symptoms, and presentation reasons did not achieve statistical significance due to small sample size. Conclusion: In conclusion, our study underscores a discernible and significant link between the administration of the Typhoid Conjugate Vaccine (TCV) and a lowered incidence of typhoid infections.

Downloads

Download data is not yet available.

References

1. Kim J-H, Im J, Parajulee P, Holm M, Cruz Espinoza LM, Poudyal N, et al. A systematic review of typhoid fever occurrence in Africa. Clin Infect Dis. 2019;69(6):492-8.

https://doi.org/10.1093/cid/ciz525

2. Batool R, Qureshi S, Haq Z, Yousafzai MT, Salam RA, Ali R, et al. Coverage survey of typhoid conjugate vaccine among children aged 6 months to 15 years in an urban slum settlement of Lyari Town Karachi, Pakistan. Plos One. 2023;18(8):e0289582.

https://doi.org/10.1016/S2214-109X(23)00606-X.

3. Qamar FN, Yousafzai MT, Sultana S, Baig A, Shakoor S, Hirani F, et al. A retrospective study of laboratory-based enteric fever surveillance, Pakistan, 2012-2014. J Infect Dis. 2018;218(4):201-5.

https://doi.org/10.1093/infdis/jiy205

4. Lightowler MS, Manangazira P, Nackers F, Van Herp M, Phiri I, Kuwenyi K, Panunzi I, et al. Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study. Vaccine. 2022;40(31):4199-210.

https://doi.org/10.1016/j.vaccine.2022.04.093

5. Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390(10):2472-80.

https://doi.org/10.1016/s0140-6736(17)32149-9

6. Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. Int J Infect Dis. 2021;108:465-72.

https://doi.org/10.1016/j.ijid.2021.05.061

7. Khan Ml, Franco-Paredes C, Sahastrabuddhe S, Ochiai RL, Mogasale V, Gessner BD. Barriers to typhoid fever vaccine access in endemic countries. Res Rep Trop Med. 2017;8(1):37-44.

https://doi.org/10.2147/RRTM.S97309

8. Qamar FN, Batool R, Qureshi S, Ali M, Sadaf T, Mehmood J, et al. Strategies to improve coverage of typhoid conjugate vaccine (tcv) immunization campaign in Karachi, Pakistan. Vaccine. 2020;8(4):697-9.

https://doi.org/10.3390/vaccines8040697

9. Yousafzai MT, Karim S, Qureshi S. Kazi M, Memon II, Junejo A, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed salmonella entcrica serotype typhi in an extensively drug-resistant outbreak setting of hyderabad, pakistan: a cohort study. Lancet Glob Health. 2021;9(8):154-62.

https://doi.org/10.1016/S2214-109X(21)00255-2

10. Olaru ID, Chingono RM, Bottomley C, Kandiye FR, Mhino F, Nyamayaro CA, et al. The effect of a comprehensive typhoid conjugate vaccine campaign on antimicrobial prescribing in children in Harare, Zimbabwe: a mixed methods study. Lancet Glob Health 2023;11(9):e1422-31.

https://doi.org/10.1016/S2214-109X(23)00319-4

11. Agarwal N, Gupta N, Surendra HS, Dutta T, Mahajan M. Typhoid Conjugate Vaccine: a boon for endemic regions. Cureus. 2024;16(3):e56454.

https://doi.org/10.7759/cureus.56454

12. Khalid K, Poh CL. The promising potential of reverse vaccinology-based next-generation vaccine development over conventional vaccines against antibiotic-resistant bacteria. Vaccines. 2023;11(7):1264.

https://doi.org/10.3390/vaccines11071264

13. Sears KT, Galen JE, Tennant SM. Advances in the development of Salmonella‐based vaccine strategies for protection against Salmonellosis in humans. J Appl Microbiol. 2021;131(6):2640-58.

https://doi.org/10.1111/jam.15055

14. Anyaegbunam ZK, Mba IE, Doowuese Y, Anyaegbunam NJ, Mba T, Aina FA, et al. Antimicrobial resistance containment in Africa: moving beyond surveillance. Biosafety Health. 2024;6(01):50-8.

https://doi.org/10.1016/j.bsheal.2023.12.003

15. Saha SK, Tabassum N, Saha S. Typhoid conjugate vaccine: an urgent tool to combat typhoid and tackle antimicrobial resistance. J Infect Dis. 2021;224(Suppl 7):S788-91.

https://doi.org/10.1093/infdis/jiab443

16. Kulkarni PS, Potey AV, Bharati S, Kunhihitlu A, Narasimha B, Yallapa S, et al. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial. Lancet. 2024;403(10436):1554-62.

https://doi.org/10.1016/S0140-6736(24)00249-6.